Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Alexion Pharmaceuticals)"
Count: 271
Selected: 0
| NCT ID | Title |
|---|
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults | ||
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | ||
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | ||
| NCT05016206 | A Study of the Cardiac Effects of Danicopan in Healthy Adults | ||
| NCT04940559 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants | ||
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction | ||
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | ||
| NCT04889677 | Study of a Single Dose of Danicopan in Healthy Participants | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | ||
| NCT03472885 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | ||
| NCT03108274 | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants | ||
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants | ||
| NCT01700179 | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants | ||
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants | ||
| NCT00675844 | An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment | ||
| NCT00401947 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection | ||
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A | ||
| NCT00350272 | Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants | ||
| NCT00312039 | Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation | ||
| NCT00040144 | Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B | ||
| NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection | ||
| NCT04709094 | A Drug Interaction Study of Danicopan | ||
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | ||
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | ||
| NCT06079359 | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | ||
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | ||
| NCT06071442 | Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine | ||
| NCT06015750 | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia | ||
| NCT05982938 | Danicopan Early Access Program | ||
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | ||
| NCT05886244 | Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | ||
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | ||
| NCT05780645 | A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | ||
| NCT05708573 | Potential Drug Interaction Between ALXN2040 and Rosuvastatin | ||
| NCT05686564 | Early Access Program for ALXN1840 in Patients With Wilson Disease | ||
| NCT05683678 | US Selumetinib Registry | ||
| NCT05644561 | Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | ||
| NCT05641311 | Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants | ||
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | ||
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease | ||
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis |
